Aimee S. Weisner net worth and biography

Aimee Weisner Biography and Net Worth

Director of Glaukos

Ms. Weisner has served as a member of our Board of Directors since 2014. From 2011 to 2019, she served as corporate vice president, general counsel of Edwards Lifesciences Corporation. From 2009 to 2010, she was engaged in private practice and served as legal advisor to public pharmaceutical and medical device companies located in Southern California. Prior to this, from 2002 to 2009, Ms. Weisner served in a number of positions at Advanced Medical Optics, Inc. (acquired by Abbott Laboratories), including corporate vice president, general counsel and secretary; executive vice president, administration, general counsel and secretary; and executive vice president, administration and secretary. From 1998 to 2002, Ms. Weisner served as corporate counsel and assistant secretary; and then vice president, assistant general counsel and assistant secretary at Allergan, Inc. Ms. Weisner currently serves on the board of directors for Oyster Point Pharma, Inc. and Lensar, Inc. Ms. Weisner holds a B.A. from California State University, Fullerton, a J.D. from Loyola Law School, Los Angeles, and began her legal career as an associate at the law firm of O’Melveny & Myers LLP.

What is Aimee S. Weisner's net worth?: The estimated net worth of Aimee S. Weisner is at least $4.54 million as of August 8th, 2024. Ms. Weisner owns 30,119 shares of Glaukos stock worth more than $4,544,355 as of December 21st. This net worth evaluation does not reflect any other assets that Ms. Weisner may own. Learn More about Aimee S. Weisner's net worth.
How do I contact Aimee S. Weisner?: The corporate mailing address for Ms. Weisner and other Glaukos executives is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. Glaukos can also be reached via phone at (949) 367-9600 and via email at [email protected]. Learn More on Aimee S. Weisner's contact information.
Has Aimee S. Weisner been buying or selling shares of Glaukos?: Aimee S. Weisner has not been actively trading shares of Glaukos during the last quarter. Most recently, Aimee S. Weisner sold 25,000 shares of the business's stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $120.00, for a transaction totalling $3,000,000.00. Following the completion of the sale, the director now directly owns 30,119 shares of the company's stock, valued at $3,614,280. Learn More on Aimee S. Weisner's trading history.
Who are Glaukos' active insiders?: Glaukos' insider roster includes Thomas Burns (CEO), Mark Foley (Director), Joseph Gilliam (CFO), Gilbert Kliman (Director), Marc Stapley (Director), Alex Thurman (CFO), and Aimee Weisner (Director). Learn More on Glaukos' active insiders.
Are insiders buying or selling shares of Glaukos?: During the last year, insiders at the medical instruments supplier sold shares 38 times. They sold a total of 478,700 shares worth more than $45,158,980.23. The most recent insider tranaction occured on December, 11th when Director Gilbert H Kliman sold 2,000 shares worth more than $288,020.00. Insiders at Glaukos own 6.4% of the company. Learn More about insider trades at Glaukos.
Information on this page was last updated on 12/11/2024.

Aimee S. Weisner Insider Trading History at Glaukos

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/8/2024	Sell	25,000	$120.00	$3,000,000.00	30,119
3/4/2016	Buy	2,500	$16.03	$40,075.00
11/12/2015	Buy	2,500	$21.83	$54,575.00	2,500

Aimee S. Weisner Buying and Selling Activity at Glaukos

Glaukos Company Overview

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Today's Range

Now: $150.88

$141.53

$151.12

50 Day Range

MA: $138.05

$127.60

$150.88

2 Week Range

Now: $150.88

$74.75

$151.12

Volume

1,054,006 shs

Average Volume

576,626 shs

Market Capitalization

$8.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.